Please login to the form below

Not currently logged in
Email:
Password:

neuroendocrine

This page shows the latest neuroendocrine news and features for those working in and with pharma, biotech and healthcare.

Novartis launch NET cancer community app

Novartis launch NET cancer community app

Following its release of a remote clinical trial app, Novartis has honed in on digital once again, this time launching an app designed to support the Neuroendocrine Tumour (NET) cancer community.

Latest news

  • AAA board presses go on $3.9bn Novartis takeover AAA board presses go on $3.9bn Novartis takeover

    With the acquisition, Novartis is aiming to add AAA’s Lutathera (Lutetium Lu177 dotatate) for treating gastroenteropancreatic neuroendocrine tumours (NET) – approved in the EU and heading for an FDA decision towards

  • Novartis to buy French radiopharma specialist AAA for $3.9bn Novartis to buy French radiopharma specialist AAA for $3.9bn

    The Swiss pharma giant said this morning that the deal would help strengthen its cancer therapy businesses, adding an approved radiopharmaceutical drug - Lutathera (177Lu- oxodotreotide) for gastroenteropancreatic neuroendocrine (GEP-NET) tumours

  • AAA’s orphan drug Lutathera wins EU green light AAA’s orphan drug Lutathera wins EU green light

    Advanced Accelerator Applications’ (AAA) Lutathera (lutetium oxodotreotide) has received European approval to treat adults with unresectable or metastatic, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours. ... Known as

  • CHMP backs three immuno-oncology drugs for solid tumours CHMP backs three immuno-oncology drugs for solid tumours

    Advanced Accelerator Applications secured a recommendation for Lutathera (lutetium [177Lu] oxodotreotide) - for the treatment of gastro-entero-pancreatic neuroendocrine tumours - and Ipsen got the nod for Xermelo (telotristat ethyl) as a

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    For Ipsen, the deal continues its drive to expand its oncology franchise, currently headed by hormonal therapy Somatuline for neuroendocrine tumours and Cabometyx (cabozantinib) for advanced renal cell carcinoma.

More from news
Approximately 1 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Last year the firm’s oncology portfolio accounted for 57% of its 1.6bn group sales, bringing in 904.8m with Somatuline (lanreotide) - a treatment for neuroendocrine tumours as well as ... leadership in neuroendocrine tumours - any therapeutic solutions

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.

  • Pharma deals during September 2013 Pharma deals during September 2013

    from Camarus, paying an undisclosed milestone included in their $700 million deal signed two years ago for the indications acromegaly and neuroendocrine tumours.

  • Pharma deals during February 2013 Pharma deals during February 2013

    Roche has acquired an exclusive licence from Chiasma for Octreolin (in phase III), an orphan designated oral treatment in US for acromegaly with a neuroendocrine tumour indication to follow.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics